PL3440105T3 - Receptory komórek t - Google Patents

Receptory komórek t

Info

Publication number
PL3440105T3
PL3440105T3 PL17717845.6T PL17717845T PL3440105T3 PL 3440105 T3 PL3440105 T3 PL 3440105T3 PL 17717845 T PL17717845 T PL 17717845T PL 3440105 T3 PL3440105 T3 PL 3440105T3
Authority
PL
Poland
Prior art keywords
cell receptors
receptors
cell
Prior art date
Application number
PL17717845.6T
Other languages
English (en)
Inventor
Conor HAYES
Linda HIBBERT
Nathaniel LIDDY
Tara MAHON
Marine RAMAN
Original Assignee
Immunocore Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Limited filed Critical Immunocore Limited
Publication of PL3440105T3 publication Critical patent/PL3440105T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL17717845.6T 2016-04-08 2017-04-07 Receptory komórek t PL3440105T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606009 2016-04-08
PCT/GB2017/050985 WO2017175006A1 (en) 2016-04-08 2017-04-07 T cell receptors

Publications (1)

Publication Number Publication Date
PL3440105T3 true PL3440105T3 (pl) 2022-08-29

Family

ID=58548761

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17717845.6T PL3440105T3 (pl) 2016-04-08 2017-04-07 Receptory komórek t

Country Status (31)

Country Link
US (2) US11505590B2 (pl)
EP (2) EP4023668A1 (pl)
JP (1) JP7254519B2 (pl)
KR (1) KR102473964B1 (pl)
CN (1) CN109563148B (pl)
AU (2) AU2017246693B2 (pl)
BR (1) BR112018070741A2 (pl)
CL (1) CL2018002859A1 (pl)
CO (1) CO2018011972A2 (pl)
CR (1) CR20180531A (pl)
CY (1) CY1125331T1 (pl)
DK (1) DK3440105T3 (pl)
ES (1) ES2914648T3 (pl)
HR (1) HRP20220865T1 (pl)
HU (1) HUE059159T2 (pl)
IL (2) IL262144B2 (pl)
LT (1) LT3440105T (pl)
MA (1) MA44608B1 (pl)
MD (1) MD3440105T2 (pl)
MX (1) MX2018012318A (pl)
MY (1) MY198621A (pl)
PE (2) PE20190335A1 (pl)
PH (1) PH12018502158B1 (pl)
PL (1) PL3440105T3 (pl)
PT (1) PT3440105T (pl)
RS (1) RS63371B1 (pl)
SG (1) SG11201808797XA (pl)
SI (1) SI3440105T1 (pl)
SM (1) SMT202200306T1 (pl)
UA (1) UA129144C2 (pl)
WO (1) WO2017175006A1 (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020555A1 (en) 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
KR20190059874A (ko) * 2016-04-08 2019-05-31 어댑티뮨 리미티드 T 세포 수용체
PL3440105T3 (pl) 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
BR112020006643A2 (pt) 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
WO2019133443A1 (en) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Modified t cell receptors
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
CA3094468A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
ES2974424T3 (es) 2019-01-17 2024-06-27 Immunocore Ltd Formulaciones
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
KR20220030933A (ko) 2019-05-08 2022-03-11 메디진 이뮤노테라피스 게엠바하 조작된 t 세포
BR112021025548A2 (pt) * 2019-06-18 2022-05-17 Regeneron Pharma Receptores de células t mage-a4 e métodos de uso dos mesmos
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
GB201915282D0 (en) * 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
CR20220256A (es) * 2019-12-18 2022-08-31 Hoffmann La Roche Anticuerpos que se unen a hla-a2/mage-a4
KR20260017503A (ko) 2020-02-14 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
WO2021236548A1 (en) * 2020-05-18 2021-11-25 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US11912771B2 (en) 2021-03-09 2024-02-27 Cdr-Life Ag MAGE-A4 peptide-MHC antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
WO2023099606A1 (en) 2021-12-01 2023-06-08 Immunocore Limited Treatment of mage-a4 positive cancer
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117106060A (zh) * 2022-05-17 2023-11-24 香雪生命科学技术（广东）有限公司 一种识别mage的高亲和力t细胞受体及其应用
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
MX2025001960A (es) 2022-08-18 2025-05-02 Immunocore Ltd Moléculas de unión multidominio
KR20250051727A (ko) 2022-08-18 2025-04-17 이뮤노코어 리미티드 멀티-도메인 결합 분자
KR20250051722A (ko) 2022-08-18 2025-04-17 이뮤노코어 리미티드 멀티-도메인 결합 분자
CA3265218A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd MAGE A4 SPECIFIC T LYMPHOCYTE RECEPTOR FUSION PROTEINS
KR20250067130A (ko) * 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
CN119552258B (zh) 2023-09-01 2025-11-07 北京智仁美博生物科技有限公司 结合hla-a02/mage-a4复合体的多种抗体及其用途
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
GB202315181D0 (en) 2023-10-03 2023-11-15 Immunocore Ltd Peptide-HLA binding molecules
WO2025087436A1 (zh) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 基于t细胞受体的多特异性多肽分子及其组合物和用途
WO2025094054A1 (en) 2023-11-01 2025-05-08 Immunocore Limited Method for purifying small multi-domain proteins
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6685698A (en) 1997-03-07 1998-09-22 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
WO1999018129A1 (en) 1997-10-02 1999-04-15 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
WO2000020445A2 (en) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP4972264B2 (ja) 1999-12-06 2012-07-11 ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 高親和性ｔｃｒタンパク質および方法
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
JP2005537891A (ja) 2002-09-10 2005-12-15 ユーロ−セルティーク エス．エイ． 血液成分の非侵襲的測定のための装置及び方法
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
DE60327795D1 (de) 2002-11-09 2009-07-09 Immunocore Ltd T zell rezeptor "display"
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
NZ561338A (en) 2005-04-01 2010-04-30 Immunocore Ltd High affinity HIV T cell receptors
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
ES2834070T3 (es) 2011-09-15 2021-06-16 Us Health Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7
WO2013053021A1 (en) * 2011-10-14 2013-04-18 Cephalon Australia Pty Ltd ANTIBODIES TO CD1d
LT3424947T (lt) 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
US10377808B2 (en) 2013-01-29 2019-08-13 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch High avidity antigen recognizing constructs
WO2014160030A2 (en) 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
WO2016007570A2 (en) * 2014-07-09 2016-01-14 The Regents Of The University Of California Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
CN107074970B (zh) 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
EP3283520B1 (en) 2015-04-13 2020-05-06 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
ES2968802T3 (es) 2016-03-16 2024-05-14 Immatics Biotechnologies Gmbh Células T transfectadas y receptores de células T para su uso en inmunoterapia contra el cáncer
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
PL3440105T3 (pl) 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules

Also Published As

Publication number Publication date
KR20180132844A (ko) 2018-12-12
CL2018002859A1 (es) 2019-04-26
IL262144B2 (en) 2024-04-01
CN109563148A (zh) 2019-04-02
HRP20220865T1 (hr) 2022-10-14
PE20190335A1 (es) 2019-03-07
EP3440105A1 (en) 2019-02-13
EP3440105B1 (en) 2022-04-27
DK3440105T3 (da) 2022-06-13
JP2019516357A (ja) 2019-06-20
UA129144C2 (uk) 2025-01-29
IL262144B1 (en) 2023-12-01
CN109563148B (zh) 2022-10-14
AU2017246693A1 (en) 2018-11-22
SI3440105T1 (sl) 2022-07-29
US12606607B2 (en) 2026-04-21
MD3440105T2 (ro) 2022-09-30
IL262144A (en) 2018-11-29
PH12018502158A1 (en) 2019-07-15
EP4023668A1 (en) 2022-07-06
RS63371B1 (sr) 2022-08-31
CR20180531A (es) 2019-06-13
IL308831A (en) 2024-01-01
US20190092834A1 (en) 2019-03-28
CY1125331T1 (el) 2025-03-28
US11505590B2 (en) 2022-11-22
AU2017246693B2 (en) 2022-07-21
RU2018135248A3 (pl) 2020-09-23
CO2018011972A2 (es) 2019-02-08
US20230322895A1 (en) 2023-10-12
MA44608B1 (fr) 2022-06-30
JP7254519B2 (ja) 2023-04-10
AU2022256131A1 (en) 2022-11-24
CA3020214A1 (en) 2017-10-12
HUE059159T2 (hu) 2022-10-28
LT3440105T (lt) 2022-05-25
MY198621A (en) 2023-09-11
SMT202200306T1 (it) 2022-09-14
RU2018135248A (ru) 2020-05-12
BR112018070741A2 (pt) 2019-02-12
MA44608A (fr) 2019-02-13
KR102473964B1 (ko) 2022-12-06
PH12018502158B1 (en) 2024-02-02
SG11201808797XA (en) 2018-11-29
PE20240693A1 (es) 2024-04-10
PT3440105T (pt) 2022-05-31
ES2914648T3 (es) 2022-06-15
WO2017175006A1 (en) 2017-10-12
MX2018012318A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
IL264425B1 (en) t cell receptors against kras-g20
ZA201806866B (en) T cell receptors
ZA201806862B (en) T cell receptors
ZA201806865B (en) T cell receptors
IL262144A (en) t cell receptors
LT4219542T (lt) T ląstelių receptoriai
ZA201701823B (en) T cell receptors
GB201522592D0 (en) T cell receptors
SG11201704155UA (en) Anti-mutated kras t cell receptors
SG11201708313QA (en) T cell receptor
PL3433270T3 (pl) Receptory limfocytów t
GB201603372D0 (en) Cell
PL3529267T3 (pl) Receptor komórek t
GB201609604D0 (en) Cell
HK40089237A (en) Anti-kras-g12d t cell receptors
GB201518991D0 (en) T cell receptors
HK1238270A1 (en) T cell receptors